List of Clario Precision Motion Opal Customers
Clario
1818 Market St. Suite 2600,
Philadelphia, 19103, PA,
United States
Philadelphia, 19103, PA,
United States
1 800-515-2279
Professional Services
7200
$965M
Since 2010, our global team of researchers has been studying Clario Precision Motion Opal customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased Clario Precision Motion Opal for Clinical Trial Management from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using Clario Precision Motion Opal for Clinical Trial Management include: UCB, a Belgium based Life Sciences organisation with 9000 employees and revenues of $5.60 billion, University of Oxford, a United Kingdom based Education organisation with 16905 employees and revenues of $4.17 billion, Newcastle University, a United Kingdom based Education organisation with 6190 employees and revenues of $699.0 million and many others.
Contact us if you need a completed and verified list of companies using Clario Precision Motion Opal, including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the software purchases.
The Clario Precision Motion Opal customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Newcastle University | Education | 6190 | $699M | United Kingdom | Clario | Clario Precision Motion Opal | Clinical Trial Management | 2024 | n/a |
In 2024 Newcastle University deployed Clario Precision Motion Opal for Clinical Trial Management to support translational and clinical research into validated digital mobility outcomes. The deployment was centered on the Translational and Clinical Research Institute and focused on clinical validation studies that integrate wearable sensor data into trial endpoint measurement.
Clario Precision Motion Opal implementation combined Opal wearable sensors with Mobilise-D algorithms to generate validated Digital Mobility Outcomes, with configuration aligned to continuous real world gait and mobility capture. Functional modules used in the deployment include sensor data capture, algorithmic processing of mobility signals, and endpoint generation for conditions such as multiple sclerosis and other mobility impairing disorders.
The program integrated Mobilise-D technical and clinical validation workflows directly into the Opal system, enabling algorithmic scoring to be produced alongside raw sensor streams for downstream analysis within clinical trial data sets. Operational coverage was research focused, with study level instrumentation and protocol alignment conducted within the United Kingdom site, and study teams using the solution to collect real world mobility and digital endpoint data.
Governance and rollout were study driven, using technical and clinical validation studies to qualify the combined Opal and Mobilise-D measurement approach for trial use. Public reporting from the collaboration explicitly indicates improved objective measurement of walking and mobility in trials, positioning the Clario Precision Motion Opal deployment as a research grade Clinical Trial Management capability for digital endpoints.
|
 |
UCB | Life Sciences | 9000 | $5.6B | Belgium | Clario | Clario Precision Motion Opal | Clinical Trial Management | 2023 | n/a |
In 2023 UCB funded and effectively deployed Clario Precision Motion Opal as part of a sponsor-supported neuroscience clinical trial led by the University of Oxford in the United Kingdom. The deployment used Clario Precision Motion Opal within Clinical Trial Management to capture gait and balance digital endpoints aimed at Parkinsons disease motor progression, establishing sponsor-level use of Opal sensor technology for clinical endpoint measurement.
Module usage inferred from the press release centers on sensor-based digital endpoint capture and time-series activity data collection, with Clario Precision Motion Opal configured to record gait and balance signals from wearable Opal sensors. Typical Clinical Trial Management workflows applied include device provisioning and calibration, protocol-aligned data capture schedules, and centralized storage of sensor-derived digital endpoints for analysis alongside clinical assessments.
Operational scope encompassed sponsor oversight and site execution at the University of Oxford, engaging clinical operations and neuroscience research functions to manage device deployment, subject monitoring, and endpoint validation. The implementation sits squarely within Clinical Trial Management workflows, supporting study operations that require continuous or periodic remote measurement of motor function in a neuroscience trial setting.
Governance reflected sponsor-funded study oversight rather than a vendor-driven pilot, enabling UCB to use Clario Precision Motion Opal for investigational endpoint evaluation. The study demonstrated earlier detection of Parkinsons motor progression compared with traditional clinical scales, signaling that Clario Precision Motion Opal can provide clinically relevant gait and balance digital endpoints for neuroscience clinical research. UCB Clario Precision Motion Opal Clinical Trial Management clinical operations
|
 |
University of Oxford | Education | 16905 | $4.2B | United Kingdom | Clario | Clario Precision Motion Opal | Clinical Trial Management | 2023 | n/a |
In 2023, University of Oxford deployed Clario Precision Motion Opal in the OxQUIP Parkinson's Disease study. The deployment integrated Clario Precision Motion Opal wearable sensors to capture digital endpoints of gait and balance as part of Clinical Trial Management activities supporting neuroscience research in the United Kingdom.
The implementation focused on continuous sensor data capture and algorithmic endpoint derivation to quantify motor symptom progression, translating raw inertial measurements into validated gait and balance metrics. Modules centered on wearable sensor acquisition, time synchronized movement analytics, and endpoint export for trial analysis, supporting clinical assessment workflows and remote monitoring.
Operational coverage was the OxQUIP study cohort and associated neurology research teams, encompassing participant wear, data collection during clinic visits and remote monitoring, and incorporation into trial assessment schedules. The deployment supported Clinical Trial Management functions including endpoint capture, data aggregation for statistical analysis, and evidence generation for Parkinson's Disease trials.
Opal-derived digital endpoints detected disease progression faster than conventional clinical rating scales, a finding that helped accelerate evidence generation for PD trials in the study. Governance emphasized protocol aligned sensor use and centralized data handling for clinical research, with workflows adjusted to incorporate digital endpoint review into investigator and outcomes committee processes.
|
Showing 1 to 3 of 3 entries
Buyer Intent: Companies Evaluating Clario Precision Motion Opal
ARTW Buyer Intent uncovers actionable customer signals, identifying software buyers actively evaluating Clario Precision Motion Opal. Gain ongoing access to real-time prospects and uncover hidden opportunities.
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated | ||
|---|---|---|---|---|---|---|---|---|
| No data found | ||||||||
FAQ - APPS RUN THE WORLD Clario Precision Motion Opal Coverage
Clario Precision Motion Opal is a Clinical Trial Management solution from Clario.
Companies worldwide use Clario Precision Motion Opal, from small firms to large enterprises across 21+ industries.
Organizations such as UCB, University of Oxford and Newcastle University are recorded users of
Clario Precision Motion Opal for Clinical Trial Management.
Companies using Clario Precision Motion Opal are most concentrated in Life Sciences and Education, with adoption spanning over 21 industries.
Companies using Clario Precision Motion Opal are most concentrated in Belgium and United Kingdom, with adoption tracked across 195 countries worldwide. This global distribution highlights the popularity of Clario Precision Motion Opal across Americas, EMEA, and APAC.
Companies using Clario Precision Motion Opal range from small businesses with 0-100 employees - 0%, to mid-sized firms with 101-1,000 employees - 0%, large organizations with 1,001-10,000 employees - 66.67%, and global enterprises with 10,000+ employees - 33.33%.
Customers of Clario Precision Motion Opal include firms across all revenue levels — from $0-100M, to $101M-$1B, $1B-$10B, and $10B+ global corporations.
Contact APPS RUN THE WORLD to access the full verified Clario Precision Motion Opal customer database with detailed Firmographics such as industry, geography, revenue, and employee breakdowns as well as key decision makers in charge of Clinical Trial Management.